In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 2181-2183

  Sanchez, Guillermo V ^a   Master, Ronald N ^b   Karlowsky, James A ^c   Bordon, Jose M ^d  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

^d Providence Hospital Washington DC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFALOTIN; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; NITROFURANTOIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; NONHUMAN; OUTPATIENT; PRIORITY JOURNAL; UNITED STATES; URINARY TRACT INFECTION;

CEFTRIAXONE; CEPHALOSPORIN RESISTANCE; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; NITROFURANTOIN; OUTPATIENTS; POPULATION SURVEILLANCE; TRIMETHOPRIM RESISTANCE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; UNITED STATES; URINARY TRACT INFECTIONS;

EID: 84858650295     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06060-11     Document Type: Article

References (22)

1. Diekema DJ, et al. 2004. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin. Infect. Dis. 38:78-85. (Pubitemid 38045876)
2. Gordon KA, Jones RN. 2003. Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). Diagn. Microbiol. Infect. Dis. 45:295-301. (Pubitemid 36555682)
3. Gupta K, Hooton TM, Stamm WE. 2001. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann. Intern. Med. 135:41-50. (Pubitemid 32619282)
4. Gupta K, et al. 2011. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin. Infect. Dis. 52:e103-e120.
5. Gupta K, Sahm DF, Mayfield D, Stamm WE. 2001. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin. Infect. Dis. 33:89-94. (Pubitemid 32554508)
6. Hooton TM. 2003. The current management strategies for communityacquired urinary tract infection. Infect. Dis. Clin. North Am. 17:303-332. (Pubitemid 36760185)
7. Hooton TM, Besser R, Foxman B, Fritsche TR, Nicolle LE. 2004. Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. Clin. Infect. Dis. 39:75-80. (Pubitemid 38879552)
8. Johnson L, et al. 2008. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am. J. Med. 121:876-884.
9. Jones ME, et al. 2004. Antibiotic susceptibility of bacteria most commonly isolated from bone related infections: the role of cephalosporins in antimicrobial therapy. Int. J. Antimicrob. Agents 23:240-246. (Pubitemid 38283592)
10. Kallen AJ, Welch HG, Sirovich BE. 2006. Current antibiotic therapy for isolated urinary tract infections in women. Arch. Intern. Med. 166:635-639.
11. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF. 2002. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob. Agents Chemother. 46:2540-2545. (Pubitemid 34793461)
12. Kashanian J, et al. 2008. Nitrofurantoin: the return of an old friend in the wake of growing resistance. BJU Int. 102:1634-1637.
13. Khawcharoenporn T, Vasoo S, Ward E, Singh K. 2010. High rates of quinolone resistance among urinary tract infections in the ED. Am. J. Emerg. Med. [Epub ahead of print.] doi:10.1016/j.ajem.2010.09.030.
14. Lautenbach E, et al. 2004. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin. Infect. Dis. 38:655-662. (Pubitemid 38333861)
15. MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. 2005. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin. Infect. Dis. 41:435-440. (Pubitemid 41099634)
16. Olson RP, Harrell LJ, Kaye KS. 2009. Antibiotic resistance in urinary isolates of Escherichia coli from college women with urinary tract infections. Antimicrob. Agents Chemother. 53:1285-1286.
17. Raz R, et al. 2002. Empiric use of trimethoprim-sulfamethoxazole (TMPSMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin. Infect. Dis. 34:1165-1169. (Pubitemid 34450662)
18. Sahm DF, Marsilio MK, Piazza G. 1999. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database-U. S. A. Clin. Infect. Dis. 29:259-263. (Pubitemid 29380180)
19. Sahm DF, Brown NP, Yee YC, Evangelista AT. 2008. Stratified analysis of multidrug-resistant Escherichia coli in US health care institutions. Postgrad. Med. 120:53-59.
20. Talan DA, et al. 2000. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA 283:1583-1590. (Pubitemid 30161514)
21. Zervos MJ, et al. 2003. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin. Infect. Dis. 37:1643-1648. (Pubitemid 37549951)
22. Zhanel GG, et al. 2006. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int. J. Antimicrob. Agents 27:468-475.